Berman Robert 4

Accession 0001562180-20-004627

CIK 0001689813other

View on SEC.gov Company Profile

Filed

Jun 21, 8:00 PM ET

Accepted

Jun 22, 9:57 PM ET

Size

23.1 KB

Accession

0001562180-20-004627

Insider Transaction Report

Form 4

Period: 2020-06-18

Biohaven Pharmaceutical Holding Co Ltd.BHVN

Berman Robert

Chief Medical Officer

Transactions

Exercise/Conversion
Common Shares
2020-06-18$0.61/sh+36,314$22,152→ 36,655 total
Sale
Common Shares
2020-06-18$76.05/sh−1,400$106,467→ 341 total
Exercise/Conversion
Common Shares
2020-06-19$0.61/sh+986$601→ 1,327 total
Sale
Common Shares
2020-06-19$75.07/sh−986$74,016→ 341 total
Exercise/Conversion
Employee Stock Option (right to buy)
2020-06-19$75.07/sh−986$74,016→ 62,700 total
Exercise: $0.61Exp: 2024-11-25→ Common Shares (986 underlying)
Sale
Common Shares
2020-06-18$75.25/sh−59,914$4,508,822→ 1,741 total
Exercise/Conversion
Employee Stock Option (right to buy)
2020-06-18−25,000→ 125,000 total
Exercise: $5.60Exp: 2025-10-22→ Common Shares (25,000 underlying)
Exercise/Conversion
Employee Stock Option (right to buy)
2020-06-18−36,314→ 63,686 total
Exercise: $0.61Exp: 2024-11-25→ Common Shares (25,000 underlying)
Exercise/Conversion
Common Shares
2020-06-18$5.60/sh+25,000$140,000→ 61,655 total

Holdings

Common Shares
(indirect: By Trust)
550,000
Common Shares
(indirect: By Trust)
240,500
Common Shares
(indirect: By Spouse)
50

Footnotes (6)

[F1]These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 - $75.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 - $76.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 - $75.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
[F5]The shares underlying this option vested in four equal installments on October 23, 2015, October 23, 2016, October 23, 2017 and October 23, 2018.
[F6]The option, representing a right to purchase a total of 225,000 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

Biohaven Pharmaceutical Holding Co Ltd.

CIK 0001689813

→

Entity typeother

Related Parties

filerCIK 0001704483

Filing Metadata

Form type: 4
Filed: Jun 21, 8:00 PM ET
Accepted: Jun 22, 9:57 PM ET
Size: 23.1 KB

View on SEC.gov